The mechanisms by which megakaryocytes (Mks) differentiate and release platelets into circulation are not well understood. Growing evidence indicates that a complex regulatory mechanism, involving Mk-matrix interactions, may contribute to the quiescent or permissive microenvironment related to platelet release within bone marrow. To address this hypothesis, in this work we first demonstrated that human Mks express and synthesize cellular fibronectin (cFN) and transglutaminase FXIII-A. Thereafter, we proposed that these two molecules are involved in a new regulatory mechanism of Mk-type I collagen interaction in the osteoblastic niche. In particular, we demonstrated that Mk adhesion to type I collagen promoted Mk spreading and inhibited proplatelet formation through the release and relocation to the plasma membrane of cFN. This regulatory mechanism was dependent on the engagement of fibronectin receptors at the Mk plasma membrane and on FXIII-A transglutaminase activity. Consistently, the same mechanism regulated the assembly of plasma FN (pFN) by adherent Mks to type I collagen. In conclusion, our data extend the knowledge of the mechanisms that regulate Mk-matrix interactions within bone marrow environment and could serve as an important step for inquiring into the origins of diseases, such as myelofibrosis and congenital thrombocytopenias that are still poorly understood.
Introduction
Hemopoietic stem cells reside in bone marrow (BM) specialized niches that dictate how they differentiate, proliferate, maturate and enter the peripheral circulation. 1, 2, 3, 4 Megakaryocyte (Mk) maturation and platelet generation is consequent to Mk migration from the osteoblastic to the vascular niche, where Mks extend proplatelets (PPF) and newly generated platelets are released into the bloodstream. 5, 6 The characteristics of the microenvironment surrounding Mks play an important role in the regulation of platelet production within BM. 3, 7 In particular, the interaction of Mk with different extra-cellular matrices (ECMs), that fill the BM spaces, seems to orchestrate their maturation in specific sites. 8 It has been demonstrated that interactions of primary human Mks with matrices supposed to fill the vascular niche, such as fibrinogen (FBG) or von Willebrand Factor (vWF), is able to sustain Mk maturation and PPF, while type I collagen, in the osteoblastic niche, totally suppresses these events and prevents premature platelet release. 7, 9 The negative regulation of PPF by type I collagen is mediated by the interaction with integrin alpha2beta1, and involves the Rho/ROCK pathway. 10, 11 However the exact subsequence of events that determine Mk interaction with ECM and therefore their regulation, is not completely understood. 12 Recent works 13 have demonstrated that the encounter between a cell and an adhesive substrate determines an initial passive interaction characterized by cell adhesion and spreading, followed by an active stage that involves actin polymerization and myosin contraction triggered by the activation of a complex cascade of signaling events. Interestingly, nothing is known about the mechanisms that regulate the dynamic of Mk-ECM interaction within the BM environment.
Recent works have demonstrated that fibronectin (FN) may represent a new regulator of Mk maturation and platelet release. [14] [15] [16] FNs are produced from a single gene, but alternative splicing of their pre-mRNA leads to the creation of several isoforms. 17, 18 The amino acid sequence variations are the consequence of the alternative processing of a single primary transcript at three conserved
sites: extra domain B (EDB) or extra type III homology B (also called EIII-B), extra domain A
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 4 (EDA or EIII-A) and type III homologies connecting segment (IIICS; V region in rat). The EDA and EDB are single exons coding for single type III repeats that are included or excluded from the FN mRNA by exon skipping. 19 EDB FN isoform protein was detected in guinea pig 20 and human 21 Mks, but its function remains poorly understood.
FN and type I collagen are cross-linked, at cellular site, by activated transglutaminases (TGs).
The TG family consists of nine known members of whom at least three are expressed in the vascular system: type 1 TG, type 2 TG and Factor XIII. 22 Recent data suggest that TGs play a role in several other processes such as cell differentiation 23 , adhesion 24 and migration. 25 In platelets TG activity depends on the presence of FXIII-A and a significant reduction of soluble fibrinogen binding in response to thrombin receptor agonist peptide (TRAP) was observed in FXIII-deficient platelets. 26 In contrast, platelet FXIII-A has been proposed to negatively regulate alphaIIbbeta3
integrin function in collagen-adherent platelets.
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In this study, we showed, for the first time, that human Mks express and synthesize cellular fibronectin (cFN). Therefore, we propose that Mk adhesion to type I collagen prevents PPF and sustains Mk spreading through a mechanism that involves FN, membrane receptors and FXIII-A TG activity. This mechanism seemed to be mediated by the exposure of cFN to the cell membrane and maintained by FN polymerization catalyzed by FXIII-A. These data address a new role to FN that, upon specific activation, could be released and thereby modulate Mk interaction with ECMs.
In this context FXIII-A catalyzed FN cross-linking at cellular sites, stabilized FN assembly and promoted the organization of ECMs. These experiments open new insight into the understanding of the role of force development and cell spreading on Mk-ECM interaction that are still unknown.
Materials And Methods

Reagents and antibodies.
Type I collagen and human plasma fibronectin were purified as previously described.
28,45
Human plasma fibrinogen was from Calbiochem (La Jolla, CA, USA). Human factor XIII was from 
Human cord blood derived Mks.
Human cord blood was collected following normal pregnancies and deliveries upon informed consent of the parents, according with the ethical committee of the IRCCS Policlinico San Matteo
Foundation and in accordance with the Principles of the Declaration of Helsinki. CD34 + cells were separated and cultured as previously described.
7,29
Evaluation of PPF and cell spreading in adhesion to different matrices.
To analyze PPF onto different adhesive substrates, 12 mm glass coverslips were coated with fibrinogen or type I collagen as described. 7 Cells at day 13 of culture were harvested and allowed to adhere for 3 or 16 hours (1 x 10 5 cells/well) at 37°C and 5% CO 2 . Cell spreading was determined as previously described. 7 In some experiments, Mks were harvested and pre-incubated with specific 
Western Immunoblotting.
Cell culture supernatants were collected and centrifuged for 10 minutes at 13,000 rpm to pellet floating cells. Adherent Mks were washed with PBS and lysed with RIPA buffer 1X (PBS with Nonidet P-40 2%, sodium deoxycholate 1%, SDS 0.2% and protease inhibitors). Protein concentrations of both the supernatant and cellular fractions were determined using the bicinchoninic acid (BCA) assay (Pierce, Milan, Italy). Equal amounts of proteins were then used for SDS-PAGE immunoelectrophoresis: secreted FN was assessed in the suspension medium by immunoprecipitation and visualized in a 7.5% reduced gel with antibody anti-fibronectin, clone IST-4, diluited 1:1000, and detected by a horseradish peroxidase (HRP)-labeled secondary antibody using enhanced chemiluminescence (ECL) (Pierce, Milan, Italy). Proteins form adherent Mks were separated by SDS-PAGE and immunostained with antibody anti-beta actin diluited 1:10000.
Flow cytometry
For DNA content analysis, low ploidy Mks at day 9 of culture were split and incubated with 25 
Pull-down assay of GTP-loaded Rho.
RhoA activity assay was performed using a Rho activation assay kit (Upstate Biotechnology, Souffelweyersheim, France) following manufacturer instructions. In parallel, total amount of Rho was determined by immunoblotting.
Assembly of fibronectin by adherent Mks under static conditions.
Mks were incubated for 30 minutes at 37 °C with 25 μg/ml of FITC-labeled human plasma fibronectin and seeded for additional 16 hours on matrices-coated coverslips and immunofluorescence microscopy was performed as above described.
DOC extraction of fibrillar deposition of fibronectin.
Mks were plated on different matrices coated well plates for 16 hours in the presence of 25µg/ml human plasma fibronectin (pFN) at 37°C. Conditioned medium was then removed and matrix was solubilized using 200 µl DOC lysis buffer (PBS, deoxycholic acid 0.1%, EDTA 2mM).
After centrifugation, the DOC-insoluble pellet was solubilized in 25 µl of 2% SDS, 20 mM TrisHCl, pH 8.8, 2 mM PMSF, 2 mM iodoacetic acid, 2 mM N-ethylmaleimide and 2 mM EDTA.
Equal volumes of DOC-insoluble samples were analyzed by SDS-PAGE using 5% polyacrylamide gels. Samples were immunoblotted and incubated with IST-4 anti-fibronectin monoclonal antibody.
To ensure the same number of cells in the experiments, in a parallel sample, cells were scraped and proteins separated by SDS-PAGE and then incubated with anti-beta actin antibody. In some experiments, DOC insoluble matrix, was visualized by immunofluorescence using the rabbit polyclonal anti-fibronectin antibody, followed by an appropriate secondary antibody. 
TG activity associated with Mk cell surface.
Intracellular TGs activity in human Mks.
Transglutaminase activity was measured by the method of Jayo A. et al. 26 Briefly, 1x10 6 Mks were lysed on ice for 20 minutes in 10 mM Tris-HCl pH 7,4, containing 0,1% Triton X-100, 140 mM NaCl, 0.4 mM PMSF and 1 mM DTT. After clearing by centrifugation, 10 μg of proteins were incubated with 400 μM biotinylated cadaverine with or without 5 mM EDTA and DMSO as negative control. After 1 hour at 37°C the reaction was stopped by adding loading buffer, then resolved in 10% SDS PAGE under reducing conditions and transferred to PVDF membranes. The membrane were incubated with peroxidase-conjugated avidin (1:5000 diluition) and visualized using the ECL chemiluminescent system. To analyze TPO effect on TG activity, cells were seeded in the presence of different concentrations of TPO (0, 50, 100 ng/ml) for 2 hours and then treated as above described.
Scanning Electron Microscopy (SEM) and immunogold.
Samples were fixed with 2.5% glutaraldehyde solution in 0.1 M Na-cacodylate buffer for 1 h at 4°C. Immunogold staining of fibronectin was performed incubating the cells for 2 hours with a polyclonal anti-fibronectin antibody followed by 1 hour incubation with a goat anti-rabbit secondary antibody coniugated with 40 nm gold beads and then dehydrated at room temperature in a gradient ethanol series up to 100%. Negative control were performed omitting primary antibody.
The specimens were mounted on aluminum stubs, sputter coated with gold and then observed with a Leica Cambridge Stereoscan 440 microscope (Leica Microsystems, Bensheim, Germany) at 17.5
kV and a magnification of 5.00 K X.
Statistics.
T test was used to analyze data, with a significant difference set at p < 0.05. Data are presented as mean ± S.D of at least three different experiments.
Results
Human megakaryocytes express and synthesize cFN
Mks were derived from human umbilical cord blood progenitor cells and expression of cFN, along with the two isoforms EDA and EDB, were analyzed by RT-PCR. As shown in Figure 1A EDA fibronectin RT-PCR revealed a 374 and 104 bp amplication products corresponding respectively to EDA+ fibronectin and EDA spliced fibronectin mRNA sequence, while EDB RT-PCR revealed a 413 and 143 bp products corresponding to the EDB+ fibronectin and spliced EDB isoform, the RT-PCR for total fibronectin (FN1) revealed a 419 bp product. 30 Further, cFN was also detected in Mk cytoplasm by a polyclonal antibody created in our laboratory 28 ( Figure 1B ) and a specific antibody against the EDA isoform (clone 3E2) ( Figure 1C ). Finally, cFN relocated to Mk membrane upon Figure 1D) . Overall, these results demonstrated that cFN was expressed by human Mks with a prevalence of the EDA+ isoform and was actively involved in Mk activation.
cFN differently modulates Mk adhesion to bone marrow ECMs
In order to analyze the role of cFN in regulating Mk-ECM interaction, mature Mks were plated on two different bone marrow ECMs: type I collagen, known to inhibit Mk maturation and PPF 11 through the Rho-ROCK pathway, or FBG, known to support Mk maturation and PPF. 3 After three hours incubation, about 25% of Mks were spread on both ECMs (Figure 2A) , however, prolonging incubation at sixteen hours, Mks on FBG returned round and started to extend proplatelets ( Figure 2B ), while Mks on type I collagen remained spread and did not proceed on maturation ( Figure 2A) . To evaluate the effect of these ECMs on Mk differentiation, low ploidy
Mks at day 9 of culture were also cultured with type I collagen or FBG for 4 days, but no significant variation in ploidy level was observed ( Figure S1 ). In order to confirm the involvement of the alpha2beta1 in type I collagen dependent spreading, pull-down experiments were performed to evaluate the quantity of GTP-loaded Rho in Mks adherent to type I collagen using the GST-RBD (a fusion protein containing Rho-binding domain of Rhotekin), which selectively binds to the GTPbound form of RhoA. Levels of GTP-bound RhoA increased upon adhesion of Mks to type I collagen with respect to Mks maintained in suspension ( Figure S2 ).
Interestingly, upon adhesion to type I collagen, and not FBG, relocation of cFN to the plasma membrane was observed after three hours incubation and maintained thereafter ( Figure 2C ).
Moreover, upon Mk adhesion to type I collagen, and not FBG, cFN was also released in the supernatant as revealed by western blotting performed upon immunoprecipitation ( Figure 2D ).
Finally, Scanning Electron Microscopy (SEM) analysis confirmed that Mks on type I collagen, after three hours incubation, started to accumulate cFN on plasma membrane as revealed by immunogold staining ( Figure 2E ).
For
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Further, co-distribution analysis of alpha 5 (CD49e) and alpha2 (CD49b) subunits with cFN demonstrated a strict association between alpha5 subunit with membraneous cFN and, to a lesser extent, with alpha2 subunit in Mks spread on type I collagen ( Figure 3A) . Further, Mk spreading was evaluated, on type I collagen, upon incubation with monoclonal antibodies anti-CD49e (clone SAM-1), anti-CD49d (alpha4 subunit) (clone P1H4) or their combination. Both antibodies determined a significant decrease in Mk spreading of about 50% with respect to control Mks incubated with a non related IgG antibody, and this effect was amplified by antibodies combination ( Figure 3B ). Consistently, Mk spreading was also decreased upon incubation with RGDS peptide ( Figure 3B ).
Fibronectin assembly is dependent on Mk interaction with type I collagen
Since relocation on the plasma membrane and secretion of cFN resulted to be dependent on the interaction of Mks with type I collagen, Mk ability of organizing pFN in an insoluble matrix was also explored. Mature Mks were plated either on type I collagen or FBG and let to adhere sixteen hours previous to incubation with fluorescein isothiocyanate (FITC)-labeled fibronectin. As observed for cFN, only Mks plated on type I collagen, and not on FBG, assembled FITC-FN as revealed by immunofluorescence analysis ( Figure 4A ). Moreover analysis of pFN assembly after deoxycholic acid (DOC)-treatment revealed the presence of fibrillar pFN only when Mks were plated on type I collagen ( Figure 4A ). Consistently immunoblot analysis revealed the presence of fibrillar pFN in the DOC-insoluble fraction in Mk-type I collagen, and not in Mk-FBG co-cultures, while pFN was present in the soluble fractions of both co-cultures ( Figure 4B) .
In order to demonstrate that FN assembly was strictly dependent on integrins binding and cell contractility, in some experiments, pFN was added to Mk cultures on type I collagen, as previously described, upon either incubation with RGDS, a synthetic peptide containing the RGD sequence that inhibits integrin-related functions, or treatment with 50 μM blebbistatin, a selective antagonist Figure 4C shows an important decrease of matrix pFN assembly in the presence of both RGDS and blebbistatin with respect to control.
Finally, to verify the incorporation of endogenous EDA+ FN during pFN assembly, we performed experiments as above and stained FN assembly with both the antibody against the EDA isoform and the polyclonal antibody against FN. Figure 4D shows that pFN and cFN EDA+ isoform co-localized in the FN matrix assembly.
Expression and activity of transglutaminases in human Mks
In order to search possible mechanisms underlying matrix FN assembly by Mks, the transglutaminases (TGs) expression and localization were analyzed. Among the most well Consistently, FXIII-A was also detected at protein level by western blot analysis, using FXIII-A from human plasma as control ( Figure 5B ). Intracellular TG activity of FXIII-A in Mks was demonstrated by incorporation of biotinylated cadaverine, a small molecule amine-donor TG substrate, into different proteins in Mk lysate with the method of Jayo et al. 26 , and this activity was completely reverted upon calcium sequestering with EDTA and completely absent in the control DMSO ( Figure 5C ). Interestingly, TPO concentration was inversely associated with FXIII-A activity, as a reduction of biotinylated proteins was observed when Mks were incubated for two hours with increased TPO concentrations ( Figure S3 ).
Further, cell surface associated TG activity, presumably due to FXIII-A, was shown by the incorporation of biotinylated cadaverine into a layer of fibronectin and detected by ELISA assay upon adhesion of Mks for sixteen hours upon fibronectin ( Figure 5D ). Decreased FXIII-A activity
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From was shown upon incubation with TG inhibitors such as iodoacetamide (IAA) and cystamine (CYS) ( Figure 5D ).
Function and localization of FXIII-A in human Mks
In order to demonstrate FN-FXIII-A interaction, during the assembly of exogenous fibronectin, co-distribution of pFN and FXIII-A was analyzed. As shown in Figure 6A 
Discussion
The characteristics of the bone marrow environment play an important role in the regulation of Mk development and proplatelet formation. Type I collagen is known to inhibit proplatelet extension through the engagement of integrin alpha2beta1 9, 12 and activation of the Rho/ROCK signaling cascade with the implication of myosin IIa. 10, 11 Despite the improvement in knowledge of the biochemical niche, little is known about the complex and dynamic regulation of Mk interaction with the BM-matrix environment. 31 Demonstrating the expression of cFN and FXIII-A by human
Mks, we propose a new, more complex, mechanism underlying Mk-type I collagen interaction in the osteoblastic niche ( Figure S4 ). Consistently, a recent work 13 has described cell spreading as a dynamic process that lead to the high binding affinity. 42 The physiological implications related to matrix protein crosslinking indicate that its function is not only to stabilize these proteins, i.e. increasing their proteolytic, chemical and mechanical resistance, but also to facilitate cell adhesion and cell motility.
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Interestingly, a recent research by Jayo et al. reported that FXIII-A represents the only detectable source of TG activity by protein analysis in platelets. 26 Here we demonstrate that, among all the TGs, FXIII-A is the most expressed by human Mks at both mRNA and protein levels. Moreover 
